Summary
12X1 Chart
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board.
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, “Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial” at the 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East.
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PD TM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer's disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients. ATTENTION-AD (ANAVEX®2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference.
Anavex Life Sciences Corp. Dividends
Anavex Life Sciences Corp. Earnings
| 7 May 2025 (8 Days) Date | | - Cons. EPS | - EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 25 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 18 Jun 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2025 (8 Days) Date | | - Cons. EPS | - EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 25 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 18 Jun 2024 Date | | - Cons. EPS | - EPS |
Anavex Life Sciences Corp. (12X1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Anavex Life Sciences Corp. ever had a stock split?
Anavex Life Sciences Corp. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. CEO | XFRA Exchange | US0327973006 ISIN |
| United States Country | 40 Employees | - Last Dividend | 7 Oct 2015 Last Split | 2 Aug 2006 IPO Date |
Overview
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases affecting the central nervous system (CNS). With a strategic approach to leveraging its proprietary compounds, the company is at the forefront of addressing significant needs in the healthcare sector, particularly for conditions with limited or no effective treatments. Since its inception in 2004, Anavex has committed to exploring the potential of its drug candidates in treating a variety of CNS diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, and a spectrum of rare neurological disorders. Headquartered in New York, New York, Anavex is dedicated to advancing its clinical programs to bring innovative solutions to patients worldwide.
Products and Services
- ANAVEX 2-73
As the lead product candidate, ANAVEX 2-73 is currently under development for the treatment of Alzheimer's disease and Parkinson's disease. The therapeutic potential of ANAVEX 2-73 also extends to other central nervous system diseases, including rare diseases such as Rett syndrome - a severe neurological disorder, infantile spasms, Fragile X syndrome, and Angelman syndrome. ANAVEX 2-73's versatility demonstrates Anavex's commitment to addressing a broad range of neurological conditions.
- ANAVEX 3-71
Further in the pipeline, ANAVEX 3-71 is under clinical trials targeting the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. This drug candidate emphasizes Anavex's targeted therapeutic approach to CNS diseases, showcasing the company's innovative research in developing treatments for mental health conditions and neurodegenerative disorders.
- Preclinical Drug Candidates
- ANAVEX 1-41
Designed for the treatment of depression, stroke, and neurodegenerative diseases, ANAVEX 1-41 is at the preclinical stage, exploring its potential to address a wide array of CNS conditions. Its development underlines Anavex's commitment to expanding its treatment landscape to include mental health disorders and the consequences of cerebrovascular accidents.
- ANAVEX 1066
ANAVEX 1066 is being investigated for its potential in treating neuropathic and visceral pain. This candidate highlights Anavex's venture into pain management, an area of significant unmet medical need, particularly for patients suffering from chronic conditions.
- ANAVEX 1037
Targeting the treatment of prostate and pancreatic cancer, ANAVEX 1037 showcases Anavex Life Sciences Corp.'s expansion into oncology. Although at the preclinical stage, this candidate represents the company's efforts to explore therapeutic options beyond CNS disorders, offering potential new avenues in cancer treatment.
- ANAVEX 1-41
Contact Information
